Big Pharma's feeding frenzy carries on apace: PD-1/PD-L1 inhibitors are redefining cancer immunotherapy

Who is developing drugs for anti-microbial resistance (AMR) and Sepsis?

Something I picked up on this morning…for critical thinkers

This is a big pharma marketing social media post:

💉 𝐓𝐡𝐞 𝐥𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞 𝐨𝐟 𝐜𝐚𝐧𝐜𝐞𝐫 𝐢𝐦𝐦𝐮𝐧𝐨𝐭𝐡𝐞𝐫𝐚𝐩𝐲: PD-1/PD-L1 inhibitors are redefining cancer immunotherapy.

💉 The first PD-1/PD-L1 inhibitors were approved just 10 years ago (Keytruda and Opdivo).

💉 It’s estimated that more than 700,000 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬 𝐠𝐥𝐨𝐛𝐚𝐥𝐥𝐲 have been treated with PD-1/PD-L1 inhibitors since their introduction.

💉 The global market for PD-1/PD-L1 inhibitors is predicted to reach $110 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 2031.

💉 Currently, there are 9 FDA-approved PD-1/PD-L1 inhibitors:

⚆ Keytruda (pembrolizumab) – Merck
⚆ Opdivo (nivolumab) – Bristol Myers Squibb
⚆ Tecentriq (atezolizumab) – Roche/Genentech
⚆ Imfinzi (durvalumab) – AstraZeneca
⚆ Bavencio (avelumab) – Merck Group/Pfizer
⚆ Libtayo (cemiplimab) – Regeneron/Sanofi
⚆ Jemperli (dostarlimab) – GSK
⚆ Zynyz (retifanlimab) – Incyte
⚆ Loqtorzi (toripalimab) – Coherus BioSciences/Shanghai Junshi…